Shilpa Medicare subsidiary completes successful Brazilian audit

Shilpa Pharma Lifesciences Limited, Unit-1, a 100% subsidiary of Shilpa Medicare, announced today that it has successfully completed a Good Manufacturing Practice (GMP) inspection by ANVISA, the Brazilian regulatory authority. The audit, which took place between June 30 and July 4, 2025, concluded with no critical or major observations. The company noted that some other observations and recommendations were discussed during the inspection, which are procedural in nature. Shilpa Medicare has committed to responding to the agency with an appropriate Corrective and Preventive Action (CAPA) plan regarding the recommendations.